Home > Journals > Minerva Chirurgica > Past Issues > Minerva Chirurgica 2008 December;63(6) > Minerva Chirurgica 2008 December;63(6):497-509





A Journal on Surgery

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,877




Minerva Chirurgica 2008 December;63(6):497-509

language: English

Laparoscopic intraperitoneal chemohyperthermia (IPCH) for gastrointestinal malignancies: indications and results

Chouillard E.

Department of General and Minimally invasive Surgery Centre Hospitalier Intercommunal, Poissy, France


Combining cytoreductive surgery (CRS) and intraperitoneal chemohyperthermia (IPCH) is the most promising new treatment for peritoneal carcinomatosis (PC) from colorectal cancer or from gastric cancer. It is not indicated for all patients with PC, and the results achieved by international experts in this field might not be replicated in routine clinical practice. Patients with good performance status, a low volume of peritoneal disease, and no extra-abdominal metastases are more likely to benefit from the combined treatment. Disease extent should be assessed at the time of the primary cancer operation, so that IPCH as an adjuvant treatment for appropriately selected patients can be administered. In this setting, laparoscopy could be interesting. Repeat CRS and IPCH in patients with diffuse peritoneal recurrence should be approached with caution and may be indicated only with effective second-line intraperitoneal chemotherapies. Finally, in some cases of intractable ascitis, patients who are not candidates for CRS, could be treated by merely palliative laparoscopic IPCH. A high level of training, expertise, and infrastructure is needed to optimize safety for both staff and patient. Therefore, concentrating services in a center with experience is likely to increase quality of care for these patients.

top of page

Publication History

Cite this article as

Corresponding author e-mail